Bailey Schultz, PhD

Estimates suggest that a quarter of the world’s population has been infected with Mycobacterium tuberculosis, which causes tuberculosis (TB) and kills more people than any other pathogen. The relationship between TB and cancer is bidirectional: a history of TB is associated with a higher risk of developing cancer (especially respiratory cancers), while many cancers and chemotherapies increase the risk of contracting TB by weakening the immune system, and some immunotherapies can even reactivate dormant TB infections. Better anti-TB drugs are urgently needed, but drug development efforts have been hampered by an incomplete molecular-level understanding of how M. tuberculosis grows and divides. Dr. Schultz is using genome-wide CRISPR-based approaches to identify and study genes that regulate mycobacterial cell growth and division. His work will point to new drug targets and help anticipate possible routes of antibiotic resistance, hopefully leading to new treatments for TB that will ease its burden on cancer patients. Dr. Schultz received his PhD from Harvard University, Cambridge, and his BS from Stanford University, Stanford.